Long-term follow-up of people with Parkinson's disease or MSA who received AB-1005
Follows people with Parkinson's disease or MSA who earlier received AB-1005 gene transfer.
Key facts
- Who runs it
- AskBio Inc
- Where
- Columbus and San Francisco, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- AB-1005 Long-Term Follow-up Study
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 132 people, planned
- Started
- 4 Sept 2025
- Expected to end
- 30 Mar 2038
- Type of study
- Observational, 2 groups
- Treatments tested
- Observation
- Record updated
- 2 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who took part in an earlier AB-1005 study. It follows them over the long term to check safety and how long effects last.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P).
- Earlier treatment
- People must be or have been enrolled in an interventional AB-1005 study.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- PD and MSA-P participants that are or were enrolled in an interventional AB-1005 study and provide informed consent
Who cannot take part
- There are no exclusion criteria
Where in United States
Also in 1 other country, 2 sites
- Ohio State UniversityColumbus, United StatesEnrolling by invitation
- University of California San FranciscoSan Francisco, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.
The 2 groups in the trial
- Participants with PD
Treatment: Observation
- Participants with MSA-P
Treatment: Observation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants With Parkinson's Disease or Multiple System Atrophy
- Plain-language title
- Long-term follow-up of people with Parkinson's disease or MSA who received AB-1005Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 October 2025